in-vivo PK Studies

WuXI's unrivaled API development platform provides our client with a robust platform to bring their drug to market. With a proven track record of success and trust in bringing life changing therapeutics to market, we are a go-to partner for clients looking for tailored and customized drug development and m...

Our bioavailability toolbox offers a customizable solution to your drug delivery challenges. 

- Spray-Dried Dispersion (SDD)
- Hot Melt Extrusion (HME)
- Nano-suspensions & Lipid Nanoparticles 
- Softgel & Liquid Filled Capsules
- Injectable Formulations\

WuXi TIDES's Peptide platform includes a complete offering of services to bring your protein therapeutic to market faster while supporting a wide variety of conjugates including PPMO, Peptide-Antibody, Peptide-Linkers.

Services include but are not limited to: - Comprehensive Discovery Service...

WuXi TIDES has a robust and integrated Oligo API Platform, offering R&D and manufacturing services from preclinical to commercial scale and operating out of our US FDA inspected facility based in Changzhou, China. We support the development and manufacture of a variety of oligonucleotide modalities inc...

Our Jinshan and Changzhou sites are equipped with multiple R&D labs as well as a dedicated cGMP HP Kilo lab and plant for producing and manufacturing highly potent APIs (HPAPI's), antibody drug conjugates (ADC's), payloads, and payload-linkers. We currently offer drug product manufacturing at STA’...

Our comprehensive suite of analytical services help to supplement the development and manufacture of your product, ensuring high quality and consistency throughout the process.

Services include: 
- Analytical method development and validation  
- API and drug product release tes...

WuXi STA offers a wide range of tailored  services and solutions for clients developing injectable formulations. Form types include solution, emulsion, sterile powder (lyophilized) and liposome. Our offering includes formulation development, performance analysis and characterization testing, and fill/...

WuXi STA's dedicated Global Regulatory Affairs CMC teams offers comprehensive CMC documentation support for IND, CTA, MAA, and NDA applications in western countries and China. Our highly experienced team works with your NCE programs to prepare Module 2 and Module 3 of your regulatory dossier through foreca...

At WuXi STA, we understand the need for flexibility at the early stages of clinical testing and how aspects such as effective dose, stability and compliance requirements can change your needs abruptly. Our packaging team will work with you to collect the relevant data and test various packaging options as ...

WuXI STA's comprehensive drug product development platform for oral dosage forms offers our clients a complete line of solutions from pre-formulation development through to final product manufacture at commercial scale. Our capabilities include; 

• Solid oral tablet/capsule (including liquid...

Your innovative therapy is ready to reach a key milestone with the IND date quickly approaching. You need a reliable partner to formulate and manufacture your therapy to meet the IND filing requirements and the dose needs for phase I studies fast.

Every innovation is unique so your partner needs...

When your CMC projects approach the final step to commercial approval, you need to consider how to be sure your drugs successfully reach your intended markets. 

Regulatory agencies have different requirements and timing. Trust in the right partner so you don’t need to worry abou...

Biotech and pharma innovators are facing considerable challenges to find CDMO partners with capacity and capability to quickly develop and deliver high-quality CTM with flexible options+

The journey for new therapies is long; wondering if a proven therapy will be produced and distributed efficiently to reach the intended markets as soon as possible should not be another burden

A Case Study of WuXi Speed and Service for a client. The project, which encompassed an integrated CMC approach to bring a molecule to IND phase was completed in 10 months

WuXi will use its new modality platform to provide an end-to-end solution for oligonucleotide peptide

WuXi STA's IND Enabling Preformulation Package (IEPP) is an integrated developability assessment service for new chemical entities (NCEs) to efficiently identify challenges and solutions earlier for higher success rates and lower overall costs. This video explains the package and process.

The purchase of BMS's Couvet, Switzerland facility adds commercial-scale production capacity for capsule and tablet dosage forms

F2CS - fast to clinical supply service package delivers reliable clinical trial materials (CTM) fast with flexible options custom developed by highly experienced integrated teams equipped with advanced technologies, working in parallel to save time.

WuXi STA has been deeply involved in the CDMO industry for more than ten years. In the year of 2020 alone, WuXi STA served more than 470 customers worldwide, supporting 13 NDA approvals globally including 5 from US FDA, 4 from EU EMA, 2 from China NMPA and 2 from Japan PMDA.  Dr. Minzhang Chen, CEO of WuXi STA, commented: “Thanks to our partners for their recognition of WuXi STA, and we will continue to leverage our end-to-end CMC platform, along with the global standard quality systems to empower more partners to accelerate their pathway to market for the benefit of global patients.”

WuXi STA's pre-formulation package IEPP (IND Enabling Pre-formulation Package) helps you select the best drug candidates at late discovery phase and develop the most suitable formulation for phase I in 8-12 weeks, 

STA Pharmaceutical, a WuXi AppTec company (WuXi STA), a leading contract development and manufacturing organization (CDMO) announces that three of its sites in China have successfully passed pre-approval inspections (PAI) by the China National Medical Products Administration (NMPA) concurrently for an innovative drug from its partner. 

The achievement validates the company's CMC capabilities and quality

STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – today announced the opening of its large-scale oligonucleotide oligonucleotide active pharmaceutical ingredient (API) manufacturing facility in Changzhou, China. This significant milestone marks WuXi STA's establishment of a comprehensive one-stop platform to support the process R&D and manufacture of oligonucleotide APIs from preclinical to commercial. It enables customers around.

Bristol Myers Squibb (NYSE: BMY) and WuXi STA – a subsidiary of WuXi AppTec – today announced that WuXi STA has agreed to purchase Bristol Myers Squibb’s manufacturing facility in Couvet, Switzerland. The Couvet site will be the first facility in Europe for WuXi STA, a leading Contract Development and Manufacturing Organization. The acquisition will enhance WuXi STA’s existing capabilities while growing capacity to support its partners’ life-saving work.

The acquisition will expand the CDMO's capabilities and capacity to serve European markets

The Wuxi companies will provide process development, scale-up, and GMP to advance Antengene's ADC program to clinical stage